January 29th 2023
Patients diagnosed with diabetic retinopathy may be particularly vulnerable to periods of low glucose, and keeping glucose levels stable should be an important part of glucose control.
January 10th 2023
The company will add programs in diabetic macular edema and myopia as it completes pre-clinical studies.
December 23rd 2022
In this preliminary study, researchers found that renal function might affect the response to IVBI treatment in patients with DME.
December 19th 2022
Company officials point out that RZ402 is an oral therapy being developed as a potential alternative to invasive and suboptimal injections into the eye.
December 14th 2022
The IDMC recommended continuation of the study based upon the outcome of the futility analysis.
Pipeline reveals bright future for combating diabetic eye disease
Despite the latest advances in anti-VEGF therapy, a small group of patients do not achieve improved vision. Ophthalmologists are looking for options.
FDA approves first drug that can delay onset of Type 1 diabetes
Diabetes can damage the eyes over time and cause vision loss, even blindness. Delaying the disease can also delay any onset of vision problems, including diabetic retinopathy and diabetic macular edema.
Study: US ophthalmology residency programs rank last for diversity
According to UC Davis researchers, more needs to be done for the field to reflect ethnic and racial diversity across the country.
AI-empowered diagnostic retina scans can help prevent heart and kidney diseases
Mediwhale, an AI diagnostics company, aims for FDA approvals to increase non-invasive, early detection to save lives. Reti-Intelligence uses a simple fundus camera to capture images of the eye, and then within one minute the AI algorithm provides the disease risk assessment.
EP. 5: EyeCon 2022: Last chance to earn those end-of-year CME credits
This December, the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide attendees with an end-of-year opportunity to meet their continuing medical education requirements. This activity has been approved for 12.50 AMA PRA Category 1 Credits™.
EYP-1901: A look at DAVIO and PAVIA clinical trial updates
Jay S. Duker, MD, chief operating officer of EyePoint Pharmaceuticals, highlights the Phase 1 and Phase 2 DAVIO clinical trials for EYP-1901 in wet age-related macular degeneration. The company also announced the first patient has been dosed in the Phase 2 PAVIA trial of EYP-1901 for nonproliferative diabetic retinopathy.
Private practice vs academics: What do young ophthalmologists need to know?
Nicole Bajic, MD, and Neel S. Vaidya, MD, MPH, share their insights from when they were at this crossroads. Learn more clinical pearls on topics like this and more at Real World Ophthalmology’s virtual conference, “Top 10 Things I Wish I Knew Sooner,” this Saturday, November 5.
KYS Vision: clinical outcomes of remote physiologic monitoring for chronic retinal conditions
The study is one of the first clinical trials to validate the clinical utility of real-world remote physiologic monitoring using an on-demand vision-as-a-service extension to the specialty retina clinic to enable remote monitoring of patients with chronic diseases such as AMD, diabetic retinopathy, and other retinal conditions.
Verana Health + AAO IRIS Registry joint initiative yields 3.5 million ophthalmic images
Lawrence Whittle, Chief Commercial Officer for Verana Health, explains what the significance of imaging data linked with electronic health record data means for patient outcomes.
Replay launches HSV gene therapy company focused on retinal eye disease
Replay is launching Eudora, an HSV gene therapy company that will target genetic retinal diseases.
Prevent Blindness offers educational resources for November’s Diabetes-related Eye Disease Awareness Month
Prevent Blindness offers videos, fact sheets, social media graphics and PowerPoint presentations to help ophthalmologists educate the public on the potential effects diabetes may have on vision.
App brings virtual eye care to Bangladesh
The EyeBuddy app will bring telehealth to eye doctors in the coming months, connecting patients across Bangladesh with ophthalmologists at a major eye-care hospital.
Verana Research Network set sights on better access to clinical care
Marc Berger, Chief Operating Officer at Verana Health, highlights what a new initiative with the American Academy of Ophthalmology IRIS Registry will mean for patients and physicians.
How to express your passion through innovation: pearls for young ophthalmologists
Murtaza Adam, MD, a vitreoretinal specialist with Colorado Retina Associates, shares a few principles he has found helpful when engaging with industry or trying to execute on your own innovation.
Paladin Phase 4 study confirms fluocinolone acetonide intravitreal implant patients' reduced need for multiple treatments
Data from the Phase 4 observational real-world safety study of the intravitreal implant were presented at the annual American Academy of Ophthalmology’s 2022 annual conference in Chicago.
COVID-19-imposed health care restrictions had no negative effects on status of DME
DME showed small significant improvement in study cohort.
Center-involved DME resolves faster with faricimab than aflibercept
The data analysis indicated that patients achieved robust visual gains and central subfield thickness reductions with faricimab dosed every 8 weeks and with PTI dosing up to every 16 weeks. The gains were sustained through year 2 of the trials.
European Commission approves faricimab for nAMD, DME
Faricimab simultaneously targets and inhibits two disease pathways involving Ang-2 and VEGF-A linked to a number of vision-threatening retinal conditions.
Ashvattha Therapeutics enrolls first patient in Phase 2 study of D-4517.2 for treatment of wet AMD, DME
The first stage of the study will evaluate the safety and relative pharmacodynamic effect of different doses of subcutaneously administered D-4517.2 compared to intravitreal injection of aflibercept, an approved therapy, in both wet AMD and DME patients up to 12 weeks.
MOA of Faricimab and 2-Year Data Review
David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, review the dual mechanism of action of faricimab as well as the 2-year update in the TENAYA, LUCERNE, YOSEMITE, and RHINE trials.
Implications of Treat-and-Extend With Faricimab in AMD
Drs David A. Eichenbaum and Caroline Baumal discuss implications of the treat-and-extend approach with faricimab in patients with wet AMD.
AMD and DME: Factors Affecting Treatment Selection and the Importance of Shared Decision-Making
Retina specialists discuss which factors impact treatment selection and how to incorporate shared decision-making into treatment selection when treating patients with AMD and DME.
Impact of AMD and DME on Quality of Life
David A. Eichenbaum, MD, FASRS, and Caroline Baumal, MD, discuss how AMD and DME impact a patient’s quality of life.
Innovent announces first patient dosed in Phase 1 study of IBI324 in patients with diabetic macular edema
According to the company, this Phase 1 dose escalations study will evaluate the safety and tolerability of intravitreal injection of IBI324 in subjects with DME.
FDA approves ranibizumab-eqrn as a biosimilar product interchangeable with ranibizumab injection for all five indications
Retina indications for which ranibizumab-eqrn is interchangeable include neovascular (wet) age-related macular degeneration; macular edema following retinal vein occlusion; diabetic macular edema; diabetic retinopathy, and myopic choroidal neovascularization.
Wills Eye Hospital’s medical staff expands with addition of four physicians
The doctors will join the Cataract and Primary Eye Care, Glaucoma, and Retina Services.
Paladin Phase 4 study confirms durability of fluocinolone acetonide intravitreal implant
Treatment and reduces burden of care, providing a treatment option for patients diagnosed with diabetic macular edema.
AI and tele-ophthalmology comparable for diagnosing diabetic retinopathy
According to the company, new imaging options presenting opportunity for better outcomes for patients.
Tiny gene fragments revealed as crucial new players in retinal development and vision
The findings could lead to a new understanding of unexplained causes of heritable retinal diseases.
A type of ‘step therapy’ is an effective strategy for diabetic eye disease
NIH-funded clinical trial finds that starting with a cheaper drug and switching to a more expensive drug as needed leads to good vision outcomes in diabetic macular edema.
2 Clarke Drive Cranbury, NJ 08512